Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation
Clinical trial NCT06830798 · RECRUITING
Trial details
- NCT number
- NCT06830798
- Sponsor
- Alexion Pharmaceuticals, Inc.
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-05-19
- Primary completion
- 2027-11-30
- Enrollment
- 450
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.